Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Transparency task force receives hundreds of comments

This article was originally published in The Silver Sheet

Executive Summary

FDA is wading through more than 900 comments on its new transparency initiative following the task force's inaugural meeting in June. The initiative aims to identify more effective ways to explain controversial agency decisions to the public, including those relating to device recalls, enforcement actions, product approvals and other agency operations ("The Silver Sheet" June 2009). After an initial flood of comments from consumers, patients, health care professionals, industry and others, FDA reopened the comment period until Nov. 6, ahead of a second task force meeting scheduled for fall. FDA will draw on the comments as it prepares to report findings and recommendations to FDA Commissioner Margaret Hamburg by January
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT036393

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel